Conformal Medical’s Post

As #AnchorMan® Left Atrial Appendage Occluder receives official approval for market launch in China, Professor Ben He and his team from Shanghai Chest Hospital, and Professor Huimin’s Chu and his team from the First Affiliated Hospital of Ningbo University, sequentially completed the first batch of implants on March 25 and 26 after the market launch. Immediate imaging demonstrated complete occlusion and excellent outcomes, marking the beginning of clinical application of AnchorMan®. These successful implants of AnchorMan® not only signifies the nationwide commencement of large-scale clinical application, but also accelerate stroke prevention in atrial fibrillation nationwide and globally. With continued clinical application, patients with non-valvular atrial fibrillation can expect safer, more effective, and longer-lasting clinical outcomes. #LAAC #MicroPort #firstimplant #LAA #cardiology

We are thrilled to share two-year late-breaking clinical results demonstrating a statistically significant benefit with DynamX® Coronary Bioadaptor System over standard-of-care Resolute OnyxTM Drug-Eluting Stent: ·     65% reduction in target lesion failure (TLF) rate ·     68% reduction in target vessel failure (TVF) rate ·     78% reduction in TLF rate in left anterior descending (LAD) artery lesions Learn more about the BIOADAPTOR Randomized Controlled Trial (RCT) results: https://lnkd.in/ecWk4dse CE marked. Not for sale in the U.S. #EuroPCR #Bioadaptor #Medtech #Innovation #Cardiology

Female patient 35 y old post COVID myocarditis Frequent PVCs of RVIT infrolateral zone Holter study show very high burden 30% Cardiac MRI fibrosis at inferobasal zone of LV and RV walls. Failed medical therapy 3D mapping navix system Activation map 56 Ms before clINICAL QRS PVC With pace map 12/12 And unipolar Qs pattern .. One single ablation @30 watt for 1 minute ABOLISHED totally.

Did you know that within five years 43% of non-Medtronic SureScan™ SCS patients‡ may lose MR eligibility due to impedance conditions?(1) With Medtronic SureScan™ systems, patients do not lose MR eligibility due to impedance conditions. Stop by our booth at NANS to learn more about Medtronic's unmatched MRI technology. Join us today for our lunch symposium where industry leaders will review the broad comprehensive pain product portfolio, unmatched MRI access†, and discuss clinical outcomes and data on expanding indications and sensing research. #MDTPainInterventions #MRI #NANS2024 #NANS24 #PatientsFirst ‡Abbott, Boston Scientific, and Nevro (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

Exciting news from Kardium Inc. in the fight against atrial fibrillation. The PULSE-EU trial tested Kardium Inc.'s novel PFA system called the Globe Pulsed Field System. The trial included 48 patients with paroxysmal or persistent AFib who underwent ablation targeting the pulmonary veins, posterior walls, and mitral isthmuses using this spherical array catheter. The results were highly promising: 💥 100% success rates for pulmonary vein isolation and posterior wall ablation  💥 91% success for mitral isthmus ablation 💥 Short procedure times (mean 87.8 minutes) 💥 84.2% freedom from atrial arrhythmia at 1 year for paroxysmal AFib 💥 80% freedom from atrial arrhythmia at 1 year for persistent AFib While still investigational and not yet FDA approved, the PULSE-EU trial data suggests the Globe PFA system could be a game-changer for catheter ablation. #EPeeps #EP #Electrophysiology #MedTech

🌟 Exciting News from SCAI 2024 Scientific Sessions! 🌟 The latest breakthrough in cardiovascular care has arrived at SCAI 2024, unveiling significant insights into transcatheter aortic valve replacement (TAVR) with the DurAVR system. 🫀 Key Highlights: • DurAVR TAVR System: Developed by Anteris Technologies, the DurAVR system is engineered with biomimetic features to closely replicate the function of a healthy aortic valve. • Study Outcomes: A groundbreaking study presented at SCAI 2024 demonstrated exceptional results. After one year, all 28 patients who received the DurAVR valve showed no signs of severe or moderate aortic stenosis—a remarkable achievement in cardiovascular intervention. • Hemodynamic Performance: The DurAVR system exhibited superior hemodynamic performance, reflecting optimized blood flow characteristics critical for cardiovascular health. 👨⚕️ Insights from Dr. Azeem Latib: Dr. Azeem Latib, Director of Interventional Cardiology and Structural Heart Interventions at Montefiore Medical Center in New York, emphasized the transformative potential of the DurAVR system. With improved hemodynamics akin to a natural valve, the DurAVR represents a significant leap forward in TAVR procedures. 🔬What's Next? • FDA Approval: While awaiting FDA approval, the DurAVR TAVR system continues to redefine the landscape of TAVR interventions. • Future Developments: Stay updated for forthcoming data releases later this year as ongoing studies further validate the effectiveness and safety of the DurAVR system. 🖇 For more details on this groundbreaking development, visit https://lnkd.in/gGeN8sqk and stay tuned for updates! At ArchCath, we're committed to informing you about the latest cardiovascular technology advancements. Subscribe to our updates, and join us in advancing cardiovascular innovation! 🏥💙 #TAVR #HeartHealth #SCAI2024 #MedicalInnovation #Cardiology #ArchCath

The CONFORMAL Early Feasibility Study (EFS) data one-year results demonstrated durable closure for LAAO indicated patients with 97.7% seal without significant (>3 mm) leaks at 12 months, comparing favorably with marketed devices.¹ The EFS data also confirmed an impressive 97% sizing correlation between TEE and angiography, to quickly confirm CLAAS device sizing.²   1. Gray W, Conformal Early Feasibility Study: 12 Months Results. Presented at TCT 2023 2. Gray W, Real-Time Atrial Appendage Assessment for LAAO-CLAAS Device Selection: Angiography vs TEE. Presented at CRT 2023   Visit the Conformal website to learn more about the CLAAS System. https://lnkd.in/d6XdifY2 Visit the Conformal website to learn more. https://lnkd.in/eFTc4h7F #Cardiology #LAAO #data #conformalmedical #claas #Afib #CRT2024 #CardioTech #InnovationInTheHeartOfDC #ConformalMedica #interventionalcardiology #electrophysiology   CAUTION: Investigational Device The CLAAS System is limited by Federal (or United States) law to investigational use.

[PFA: Electrifying the Future of Heart Care! ⚡] PFA is an innovative technique that uses electrical fields for precision and safety, shifting away from traditional high-risk ablation. 🔍 Key Insights: 1️⃣ PFA, rooted in oncology, now shines in cardiology, showcasing its versatility. 2️⃣ With endorsements from the Heart Rhythm Society and promising trials, PFA is redefining ablation standards. 3️⃣ The PFA market is booming, projected to grow at +11% CAGR from 2023-2029. 4️⃣ Industry giants Boston Scientific and Medtronic are pioneering the PFA evolution. 5️⃣ PFA's success hinges on high current connectivity, ensuring speed and accuracy. Nextron provides robust high-current connector technology, ideally suited for PFA's specifications. 🌟 We're witnessing a paradigm shift in atrial fibrillation treatment, with PFA at the forefront. Let's embrace the future of cardiac care! 🎉 🚀Visit: https://lnkd.in/g4nCV6hn 🚀Email us: marketing@nextron.com.tw #CardiacElectrophysiology #PFA #MedicalTech

The decisions SCS patients make today can have lasting impacts, especially when it comes to MRI access†. Since up to 84% of SCS patients will need an MRI within five years(1), it's vital for healthcare providers to share the most up-to-date data on implant options when receiving informed consent from their patients.  In fact, a new independent study found that at five years post implant, 100% of Medtronic SCS patients still had MRI access†.(2) Learn more: Click here to find resources and learn about SureScan™ MRI technology, go to Medtronic.com/SCSMRI #MDTPainInterventions #SCS #MRI #MRIAccess  (1) Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine (Phila Pa 1976). 2015 1;40(9):E531-7. (2) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

In June we feature our Neuroradiology Division. In patients with intracranial atherosclerotic arterial stenosis treated with angioplasty and stent placement, procedural ischemic events may limit interventions relative to best medical therapy, suggesting that investigation to improve endovascular devices and techniques may be required to make angioplasty and stent placement safer and more effective, particularly for the benefit of patients with severe intracranial atherosclerotic stenosis who have continued ischemic events despite aggressive medical therapy. https://bit.ly/3Xna5v5 #neuroradiology